A Phase 3, Randomized, Double-Blind, Positive-controlled, Head-to-Head Monotherapy Study Comparing TLL-018 to Tofacitinib in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
Latest Information Update: 24 Nov 2023
At a glance
- Drugs TLL 018 (Primary) ; Tofacitinib
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms TARA
- Sponsors TLL Pharmaceutical
- 30 Oct 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 30 Sep 2023 to 30 Nov 2023.
- 30 Oct 2023 Status changed from not yet recruiting to recruiting.
- 01 Sep 2023 New trial record